Shire says internal synergy goals from Baxalta deal higher

(Reuters) - The chief executive of rare disease drugmaker Shire Plc on Tuesday suggested that the company could achieve much higher cost savings from its planned $32 billion acquisition of Baxalta than what was announced with the deal on Monday.